Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17

1.

Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme.

Heslinga M, Van Den Oever I, Jonker DL, Griep EN, Griep-Wentink H, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters M, Van Schaardenburg D, Nurmohamed MT.

Scand J Rheumatol. 2019 Sep;48(5):345-352. doi: 10.1080/03009742.2019.1600718. Epub 2019 Jun 18.

PMID:
31210083
2.

Change in cardiovascular risk after initiation of anti-rheumatic treatment in early rheumatoid arthritis.

Turk SA, Heslinga M, Twisk J, van der Lugt V, Lems WF, van Schaardenburg D, Nurmohamed MT.

Clin Exp Rheumatol. 2019 May-Jun;37(3):513. Epub 2019 Feb 15. No abstract available.

3.

The relationship between remission and health-related quality of life in a cohort of SLE patients.

Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, van Tuyl LH, van Vollenhoven RF, Voskuyl AE.

Rheumatology (Oxford). 2019 Apr 1;58(4):628-635. doi: 10.1093/rheumatology/key349.

PMID:
30517706
4.

USP Apparatus 4: a Valuable In Vitro Tool to Enable Formulation Development of Long-Acting Parenteral (LAP) Nanosuspension Formulations of Poorly Water-Soluble Compounds.

Forrest WP, Reuter KG, Shah V, Kazakevich I, Heslinga M, Dudhat S, Patel S, Neri C, Mao Y.

AAPS PharmSciTech. 2018 Jan;19(1):413-424. doi: 10.1208/s12249-017-0842-x. Epub 2017 Jul 28.

PMID:
28755052
5.

The Effects of 5-year Etanercept Therapy on Cardiovascular Risk Factors in Patients with Psoriatic Arthritis.

Agca R, Heslinga M, Kneepkens EL, van Dongen C, Nurmohamed MT.

J Rheumatol. 2017 Sep;44(9):1362-1368. doi: 10.3899/jrheum.161418. Epub 2017 Jun 1.

PMID:
28572461
6.

Cardiovascular risk management in rheumatoid arthritis patients still suboptimal: the Implementation of Cardiovascular Risk Management in Rheumatoid Arthritis project.

van den Oever IAM, Heslinga M, Griep EN, Griep-Wentink HRM, Schotsman R, Cambach W, Dijkmans BAC, Smulders YM, Lems WF, Boers M, Voskuyl AE, Peters MJL, van Schaardenburg D, Nurmohamed MT.

Rheumatology (Oxford). 2017 Sep 1;56(9):1472-1478. doi: 10.1093/rheumatology/kew497.

PMID:
28199724
7.

Cardiovascular Disease Reduction in Rheumatoid Arthritis by Statins: The Final Evidence?

Heslinga M, Nurmohamed MT.

J Rheumatol. 2016 Nov;43(11):1950-1952. No abstract available.

PMID:
27803339
8.

Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus.

Tsang-A-Sjoe MW, Bultink IE, Heslinga M, Voskuyl AE.

Rheumatology (Oxford). 2017 Jan;56(1):121-128. doi: 10.1093/rheumatology/kew377. Epub 2016 Nov 1.

PMID:
27803306
9.

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT.

Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Review.

PMID:
27697765
10.

Cardiovascular comorbidity in rheumatic diseases.

Nurmohamed MT, Heslinga M, Kitas GD.

Nat Rev Rheumatol. 2015 Dec;11(12):693-704. doi: 10.1038/nrrheum.2015.112. Epub 2015 Aug 18. Review.

PMID:
26282082
11.

Plasma protein corona modulates the vascular wall interaction of drug carriers in a material and donor specific manner.

Sobczynski DJ, Charoenphol P, Heslinga MJ, Onyskiw PJ, Namdee K, Thompson AJ, Eniola-Adefeso O.

PLoS One. 2014 Sep 17;9(9):e107408. doi: 10.1371/journal.pone.0107408. eCollection 2014.

12.

Mechanical bowel obstruction due to occlusion with a biliary calculus: a case of a 91-year-old woman with nausea and vomiting.

Heslinga M, Bakker J, van Houtum W, van der Jagt-Willems H.

J Am Geriatr Soc. 2014 Aug;62(8):1612-3. doi: 10.1111/jgs.12961. No abstract available.

PMID:
25113542
13.

One-step fabrication of agent-loaded biodegradable microspheroids for drug delivery and imaging applications.

Heslinga MJ, Willis GM, Sobczynski DJ, Thompson AJ, Eniola-Adefeso O.

Colloids Surf B Biointerfaces. 2014 Apr 1;116:55-62. doi: 10.1016/j.colsurfb.2013.12.054. Epub 2013 Dec 31.

PMID:
24441181
14.

Design of nanovectors for therapy and imaging of cardiovascular diseases.

Eniola-Adefeso O, Heslinga MJ, Porter TM.

Methodist Debakey Cardiovasc J. 2012 Jan;8(1):13-7.

15.

Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery.

Huang RB, Mocherla S, Heslinga MJ, Charoenphol P, Eniola-Adefeso O.

Mol Membr Biol. 2010 Oct;27(7):312-27. doi: 10.3109/09687688.2010.522117. Review.

PMID:
21028938
16.

Dynamic and cellular interactions of nanoparticles in vascular-targeted drug delivery (review).

Huang RB, Mocherla S, Heslinga MJ, Charoenphol P, Eniola-Adefeso O.

Mol Membr Biol. 2010 Aug;27(4-6):190-205. doi: 10.3109/09687688.2010.499548. Review. Corrected and republished in: Mol Membr Biol. 2010 Oct;27(7):312-27.

PMID:
20615080
17.

Fabrication of biodegradable spheroidal microparticles for drug delivery applications.

Heslinga MJ, Mastria EM, Eniola-Adefeso O.

J Control Release. 2009 Sep 15;138(3):235-42. doi: 10.1016/j.jconrel.2009.05.020. Epub 2009 May 22.

PMID:
19467275

Supplemental Content

Loading ...
Support Center